9A6-6C3 for COVID-19
c19early.org
COVID-19 Treatment Clinical Evidence
COVID-19 involves the interplay of 400+ viral and host proteins and factors, providing many therapeutic targets.
c19early analyzes 6,000+ studies for 210+ treatments—over 17 million hours of research.
Only three high-profit early treatments are approved in the US.
In reality, many treatments reduce risk,
with 25 low-cost treatments approved across 163 countries.
-
Naso/
oropharyngeal treatment Effective Treatment directly to the primary source of initial infection. -
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
-
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
-
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
-
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
-
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
-
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
-
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
-
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.
9A6-6C3 may be beneficial for
COVID-19 according to the study below.
COVID-19 involves the interplay of 400+ viral and host proteins and factors providing many therapeutic targets.
Scientists have proposed 11,000+ potential treatments.
c19early.org analyzes
210+ treatments.
We have not reviewed 9A6-6C3 in detail.
, Dual Epitope Engagement Enables Broad-Spectrum Neutralization of SARS-CoV-2 Variants by Bispecific Antibody 9A6-6C3, Research Square, doi:10.21203/rs.3.rs-7686776/v1
<title>Abstract</title> <p>Given the continuously mutating nature of SARS-CoV-2, the sensitivity of most monoclonal therapeutic antibodies has decreased to the mutants. Bispecific antibodies (BsAbs), with their unique antiviral mechanisms that enable simultaneous binding to two epitopes, offer a distinct advantage in combating the continuous viral mutation by preventing immune escape and enhancing viral neutralization. In this study, we synthesized 67 bsAbs based on the epitope distribution from antibodies isolated using single B-cell cloning from convalescent patients and phage display, 11 of which showed superior neutralization of WA1/2020 compared to their parent antibodies. One bispecific antibody (9A6-6C3), exhibiting 100-fold greater neutralizing activity than its parent antibodies, efficiently neutralized various SARS-CoV-2 variants (IC50 < 100ng/mL). Structural analysis indicates that 9A6 binds to the H-RBD epitope, encountering spatial conflict with the NTD of neighboring S monomer, while 6C3 is capable of binding to a conserved loop on S2. <italic>In vitro</italic> evidence demonstrates that 9A6-6C3 promotes the disassembly of the S protein, exposing S2, which likely contributes to its broad-spectrum neutralizing activity. In summary, we discovered a potential broad-spectrum mechanism and presented an epitope design strategy for bsAbs, offering valuable insights for the design and development of bsAbs in the fight against COVID-19.</p>